Manuel Aivado has served as our President and CEO since September 2018. Prior to this, he was our SVP, CMO & CSO since September 2014. From March 2012 until September 2014, Dr. Aivado served as vice president of clinical development and pharmacovigilance at Taiho Oncology, Inc. From October 2006 until March 2012, Dr. Aivado served as senior medical director in the clinical development group at GlaxoSmithKline, Inc. In addition, Dr. Aivado was an instructor in medicine at Beth Israel Deaconess Medical Center/Harvard Medical School. Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for ten years, during which time he was awarded the Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado is a German board-certified physician for internal medicine, hematology and medical oncology, and he received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany.
Vojo Vukovic has served as our Senior Vice President and Chief Medical Officer since November 2018. Previously, from May 2017 to November 2018, Dr. Vukovic provided consulting and advisory services to biotechnology and pharmaceutical clients, including our company. From February 2016 to May 2017, Dr. Vukovic served as senior vice president and chief medical officer at Taiho Oncology, Inc. From January 2009 to November 2015, Dr. Vukovic served as Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals, Inc., a company focused on novel oncology medicines. Prior to Synta, Dr. Vukovic served as medical director at Pfizer. He also was a member of the leadership team for Pfizer’s Oncology Radiotherapy Initiative. Dr. Vukovic received a M.Sc. in tumor biology and a Ph.D. in radiation biology from the University of Toronto, and a M.D. from University of Sarajevo.
Rick Wanstall has served as our Chief Financial Officer and Treasurer and previously as Vice President, Finance and Operations since July 2018. From July 2014 to July 2018, Mr. Wanstall served as Vice President, Finance at Moderna Therapeutics, Inc., a biotechnology company focused on drug discovery and drug development based on messenger RNA. Prior to Moderna, Mr. Wanstall served as Senior Vice President, Global Finance at Stream Global Services, Inc., a multinational business process outsourcing company, from May 2010 until July 2014. Previously, Mr. Wanstall served in management roles in finance, accounting and SEC reporting for several technology and financial services companies. Mr. Wanstall began his career at Coopers & Lybrand, LLC. Mr. Wanstall received a B.A. from Salem State College, and a M.B.A. from Babson College.
Allen Annis has served as our Senior Vice President, Research, since November 2018. Dr. Annis joined our company in November 2007 and served as our Senior Director, Biophysical and Analytical Technology, from November 2007 to September 2009, and as our Vice President of Research from September 2009 to November 2018. Previously, Dr. Annis served as Director of Technology Development at Schering-Plough Research Institute, and as Vice President of New Technologies at NeoGenesis Pharmaceuticals, Inc. While at NeoGenesis, Dr. Annis co-developed the company’s core drug discovery platform, the affinity selection-mass spectrometry-based Automated Ligand Identification System, or ALIS. Dr. Annis authored the key patents and publications that describe the ALIS technology and invented novel ALIS-based techniques to study protein-drug interactions. Dr. Annis received a M.A. and Ph.D. in chemistry from Harvard University, and a B.S. in chemistry from Georgia Institute of Technology.
Dora Ferrari has served as our Vice President, Clinical Development and Program Management since June 2019. Upon joining Aileron in November 2017, Dora has managed program oversight for our ongoing Clinical Stage programs as well as Program Management across the organization. Prior to joining Aileron, Dora spent a decade at ArQule, Inc where she was involved in Clinical Operations and Program Management, successfully leading delivery of oncology targets from discovery candidates though pivotal clinical trials. Most recently, Dora was ArQule’s Director of Clinical Development and Program Management. Dora began her pharmaceutical career in 2003 as a Clinical Research Associate for EPIX Pharmaceuticals and was a key member of the Vasovist NDA team. She has a BS in Animal Science/Pre-Vet from the University of Massachusetts, Amherst.